Royalty Report: Diagnostic, Cancer, Medical – Collection: 28718


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Diagnostic
  • Cancer
  • Medical
  • Drugs
  • Disease
  • Pharmaceuticals
  • Diagnostic Substances
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28718

License Grant
The Company, through its wholly-owned subsidiary acquired miRInform® Thyroid and Pancreas cancer diagnostic tests, other tests in development for thyroid cancer, associated intellectual property and a biobank with more than 5,000 patient tissue samples from the Seller.
License Property
miRInform Thyroid is a Panel of molecular markers which improves preoperative diagnostic accuracy for patients with indeterminate thyroid nodules.

miRInform® Pancreas was developed to aid physicians in the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive. The test evaluates expression levels of seven miRNAs in Fine Needle Aspirate (FNA) specimens of pancreatic masses.

IPSCIO Record ID: 26200

License Grant
The Licensor and the Licensee desire to collaborate on the commercialization of Thymira. Each of the parties shall use commercially reasonable efforts to achieve Commercialization on or before the first anniversary of the Effective Date.
License Property
The Licensor is a molecular diagnostics company focusing on predictive and prognostic genetic cytology and has the rights to the following diagnostic tests ThymiraTM – a diagnostic test used to differentiate between benign and malignant ‘indeterminate’ thyroid FNA lesions comprised of 4 biomarkers that measure microRNA expression levels from a sample using fine needle aspiration; and ArmiraTM – a test to diagnose kidney transplant rejection by predicting acute rejection and renal allograft function.
Field of Use
THYMIRAâ„¢ is a molecular test for indeterminate thyroid nodules and ARMIRAâ„¢, a molecular test to determine and monitor acute kidney rejection.

The Licensee is a provider of outsourced commercial services to pharmaceutical, biotechnology and medical device clients in the United States and offers sales support services, clinical educator services, digital communications, tele-detailing and full-service product commercialization solutions.

IPSCIO Record ID: 5811

License Grant
The License Agreement grants us a non-exclusive, non-transferable and non-assignable License to use Licensor’s patents, trademarks and technology rights relating to the licensed products and the processing and reporting of laboratory analyses of samples collected using the products.
License Property
The products licensed are Cholesterol Panel; Hemoglobin A1c; Prostate Screen; Thyroid Test and Anemia Test.

Cholesterol Panel (a lipid profile consisting of total cholesterol, high density cholesterol, low density cholesterol and triglycerides).  This Cholesterol Panel is the first self-collected lipid profile for dried blood sample analysis that satisfies the National Cholesterol Education Program’s rigorous performance standards. It is used in the management and determination of coronary heart disease.

Hemoglobin A1c (a test that meets the certification standards of the National Glycohemoglobin Standardization Program). This test is critical for proper blood sugar monitoring and regulation by persons affected with diabetes.

Prostate Screen (a test to determine blood levels of prostate specific antigen). This test is used to help determine abnormal prostate conditions, such as prostate cancer.

Thyroid Test (a test to determine blood levels of thyroid stimulating hormone). This test is used to help determine thyroid dysfunction and to successfully manage treatment regimens.

Anemia Test (a rapid response test – like a home pregnancy test, the results are available to the user immediately – for low hemoglobin levels). This test is used to monitor and identify the onset or change in hemoglobin levels, which is a common side effect for many disease states including HIV, chronic kidney disease and cancer.

Field of Use
Products specialize in the use of micro-sample blood transportation devices and unique scientific procedures for the clinical testing of these micro-blood samples.

IPSCIO Record ID: 4006

License Grant
The Licensor hereby grants the Licensee and its affiliates an exclusive, worldwide, perpetual, irrevocable, royalty-bearing License, with the right to grant and authorize subLicenses, under the Licensed Patents.
License Property
United States

Patent 5,798,266

August 28, 2016
Patent 6,287,521

August 28, 2016
Patent 6,689,073

November 14, 2020
Patent 6,887,210

November 14, 2020
Patent 7,128,877

August 28, 2016
Patent Application 20060030787

Field of Use
The Licensee believes that these patents will allow the Licensee to develop the Mammary Aspirate Cytology Specimen Test (MASCT) System and the specialty laboratory ahead of any competition and will give it a competitive edge in the market.

IPSCIO Record ID: 278110

License Grant
The Parties entered this agreement to develop and commercialize ficlatuzumab.  The non-opting out party shall have sole decision-making authority with respect to further development and commercialization of ficlatuzumab.

Licensor granted the perpetual, non-exclusive rights to certain intellectual property, including diagnostic data related to VeriStrat, with respect to the development and commercialization of ficlatuzumab.

License Property
Ficlatuzumab is a hepatocyte growth factor (HGF) inhibitory antibody.  Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (HNSCC) and metastatic pancreatic ductal cancer (PDAC).

VeriStrat® is Licensor’s proprietary companion diagnostic test.  VeriStrat test is a predictive and prognostic blood-based proteomic test for patients with advanced non-small cell lung cancer.

A retrospective exploratory analysis uses VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA®) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC).

Field of Use
The field of use is the treatment of non-small cell lung cancer in poor prognosis patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.